-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $9

Benzinga·12/12/2025 18:59:15
语音播报
Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $8 to $9.